Similarly, when bone marrow-derived macrophages from CD45.1 mice were transferred into CD45.2 tumor-bearing mice, D166 treatment increased the expression of M1 macrophage markers (CD86 and iNOS) in CD45.1 macrophages, whereas the expression of M2 markers decreased (Figure 5K-N). The gene discussed is CD86; the disease is neoplasm.